Search Results - "Dómine Gómez, Manuel"

NGS‐based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment by Sánchez‐Herrero, Estela, Serna‐Blasco, Roberto, Ivanchuk, Vadym, García‐Campelo, Rosario, Dómine Gómez, Manuel, Sánchez, José M., Massutí, Bartomeu, Reguart, Noemi, Camps, Carlos, Sanz‐Moreno, Sandra, Calabuig‐Fariñas, Silvia, Jantus‐Lewintre, Eloísa, Arnal, Magdalena, Fernández‐Orth, Dietmar, Calvo, Virginia, González‐Rumayor, Víctor, Provencio, Mariano, Romero, Atocha

“…Despite impressive and durable responses, nonsmall cell lung cancer (NSCLC) patients treated with anaplastic lymphoma kinase (ALK) inhibitors (ALK‐Is)…”
Get full text

Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients by Farina, Benito, Guerra, Ana Delia Ramos, Bermejo-Peláez, David, Miras, Carmelo Palacios, Peral, Andrés Alcazar, Madueño, Guillermo Gallardo, Jaime, Jesús Corral, Vilalta-Lacarra, Anna, Pérez, Jaime Rubio, Muñoz-Barrutia, Arrate, Peces-Barba, German R, Maceiras, Luis Seijo, Gil-Bazo, Ignacio, Gómez, Manuel Dómine, Ledesma-Carbayo, María J

“…Identifying predictive non-invasive biomarkers of immunotherapy response is crucial to avoid premature treatment interruptions or ineffective prolongation. Our…”
Get full text

Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP by Ospina, Aylen Vanessa, Bolufer Nadal, Sergio, Campo-Cañaveral de la Cruz, José Luis, González Larriba, Jose Luis, Macía Vidueira, Ivan, Massutí Sureda, Bartomeu, Nadal, Ernest, Trancho, Florentino Hernando, Álvarez Kindelán, Antonio, Del Barco Morillo, Edel, Bernabé Caro, Reyes, Bosch Barrera, Joaquim, Calvo de Juan, Virginia, Casal Rubio, Joaquin, de Castro, Javier, Cilleruelo Ramos, Ángel, Cobo Dols, Manuel, Dómine Gómez, Manuel, Figueroa Almánzar, Santiago, Garcia Campelo, Rosario, Insa Mollá, Amelia, Jarabo Sarceda, José Ramón, Jiménez Maestre, Unai, López Castro, Rafael, Majem, Margarita, Martinez-Marti, Alex, Martínez Téllez, Elisabeth, Sánchez Lorente, David, Provencio, Mariano

“…Introduction Recent advances in the treatment of locally advanced NSCLC have led to changes in the standard of care for this disease. For the selection of the…”
Get full text

Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer by Dómine Gómez, Manuel, Csőszi, Tibor, Jaal, Jana, Kudaba, Iveta, Nikolov, Krasimir, Radosavljevic, Davorin, Xiao, Jie, Horton, Janet K., Malik, Rajesh K., Subramanian, Janakiraman

“…Chemotherapy‐induced myelosuppression is an acute, dose‐limiting toxicity of chemotherapy regimens used in the treatment of extensive‐stage small cell lung…”
Get full text

Treatment-related hemophagocytic lymphohistiocytosis due to atezolizumab: a case report and review of the literature by Rubio-Perez, Jaime, Rodríguez-Perez, Ãngel Ricardo, Díaz-Blázquez, María, Moreno-García, Victor, Dómine-Gómez, Manuel

“…Abstract Background Immune checkpoint inhibitors avoid inhibition of T-cell responses, upregulating antitumor immune response. Moreover, a dysregulation with…”
Get full text

SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer by Borghaei, H, de Marinis, F, Dumoulin, D, Reynolds, C, Theelen, W S M E, Percent, I, Gutierrez Calderon, V, Johnson, M L, Madroszyk-Flandin, A, Garon, E B, He, K, Planchard, D, Reck, M, Popat, S, Herbst, R S, Leal, T A, Shazer, R L, Yan, X, Harrigan, R, Peters, S

“…Checkpoint inhibitor (CPI) therapy revolutionized treatment for advanced non-small-cell lung cancer (NSCLC); however, most patients progress due to primary or…”
Get more information

362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis by Spicer, James, Helland, Åslaug, Carcereny, Enric, Arriola, Edurne, Gomez, Manuel Dómine, Trigo Perez, Jose Manuel, Thompson, Jonathan, Strauss, James, Ortega Granados, Ana Laura, Felip, Enriqueta, Schmidt, Emmett, Chisamore, Michael, Madeleine, Noelly, Rayford, Austin, Lorens, Katherine, Siddiqui, Abdul, Gabra, Hani, Nautiyal, Jaya, Micklem, David, Lorens, James, Krebs, Matthew

“…BackgroundAXL is implicated in resistance to immunotherapy. Bemcentinib (BGB324), a first-in-class, oral, selective and potent AXL kinase inhibitor, enhances…”
Get full text

Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer by Levy, Benjamin P., Giaccone, Giuseppe, Besse, Benjamin, Felip, Enriqueta, Garassino, Marina Chiara, Domine Gomez, Manuel, Garrido, Pilar, Piperdi, Bilal, Ponce-Aix, Santiago, Menezes, Daniel, MacBeth, Kyle J., Risueño, Alberto, Slepetis, Ruta, Wu, Xiaoling, Fandi, Abderrahim, Paz-Ares, Luis

“…Preclinical and early clinical studies suggest that combining epigenetic agents with checkpoint inhibitors can potentially improve outcomes in patients with…”
Get full text

Association of Performance Status and Pain in Metastatic Bone Pain Management in the Spanish Clinical Setting by Dómine Gómez, Manuel, Díaz Fernández, Nieves, Cantos Sánchez de Ibargüen, Blanca, Zugazabeitia Olabarría, Luis, Martínez Lozano, Joaquina, Poza de Celis, Raúl, Trujillo Vílchez, Rafael, Peláez Fernández, Ignacio, Capdevila Castillón, Jaume, Traseira Lugilde, Susana, Esteban González, Emilio

“…Introduction Bone metastasis is the most common cause of cancer-related pain, and metastatic bone pain (MBP) is not only severe but also progressive in many…”
Get full text

Final analysis of KEYNOTE-189: Pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro) in patients (pts) with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC) by Rodriguez-Abreu, Delvys, Powell, Steven Francis, Hochmair, Maximilian, Gadgeel, Shirish M., Esteban, Emilio, Felip, Enriqueta, Speranza, Giovanna, Dómine Gomez, Manuel, Cheng, Susanna Y., Bischoff, Helge, Peled, Nir, Reck, Martin, Hui, Rina, Garon, Edward B., Boyer, Michael J., Kurata, Takayasu, Yang, Jing, Bas, Tuba, Souza, Fabricio G., Garassino, Marina Chiara

“…Abstract only 9582 Background: The phase III KEYNOTE-189 study (NCT02578680), showed significant improvements in OS and PFS with pembro + chemo vs placebo +…”
Get full text

A phase II study of bemcentinib (BGB324), a first-in-class highly selective AXL inhibitor, with pembrolizumab in pts with advanced NSCLC: OS for stage I and preliminary stage II efficacy by Felip, Enriqueta, Brunsvig, Paal, Vinolas, Nuria, Ponce Aix, Santiago, Carcereny Costa, Enric, Dómine Gomez, Manuel, Trigo Perez, Jose Manuel, Arriola, Edurne, Campelo, Rosario Garcia, Spicer, James F., Thompson, Jonathan Robert, Ortega Granados, Ana Laura, Holt, Robert J, Lorens, Katherine, Lorens, James B., Shoaib, Muhammad, Siddiqui, Abdul, Schmidt, Emmett V., Chisamore, Michael Jon, Krebs, Matthew

“…Abstract only 9098 Background: AXL is an RTK implicated in epithelial-to-mesenchymal transition and as a resistance mechanism to multiple therapies including…”
Get full text

SEOM clinical guidelines for the treatment of small-cell lung cancer by Artal Cortés, Ángel, Dómine Gómez, Manuel, Font Pous, Albert, García Campelo, Rosario, Cobo Dolls, Manuel, Isla Casado, Dolores

Get full text

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial by Paz-Ares, Luis, Dvorkin, Mikhail, Chen, Yuanbin, Reinmuth, Niels, Hotta, Katsuyuki, Hochmair, Maximilian J, Özgüroğlu, Mustafa, Ji, Jun Ho, Bondarenko, Igor, Byrne, Natalie, Shire, Norah, Goldman, Jonathan W, Batagelj, Emilio, Casarini, Ignacio, Pastor, Anea Viviana, Hartl, Sylvia, Hochmair, Maximilian J, Lamprecht, Bernd, Dos Reis, Peo, Serodio da Rocha Baldotto, Clarissa, Venkova, Violetka, Bi, Minghong, Chen, Zhendong, Han, Zhigang, Hu, Yi, Li, Wei, Ma, Shenglin, Nan, Kejun, Shu, Yongqian, Wang, Kai, Yang, Nong, Zhang, Wei, Zhao, Jun, Zhao, Yanqiu, Zhou, Caicun, Zhou, Xiangdong, Skrickova, Jana, Hilgers, Werner, Moro-Sibilot, Denis, Bischoff, Helge, Lang, Susanne, Fülöp, Anea, Horváth, Zsolt, Laczó, Ibolya, Losonczy, György, Pápai Székely, Zsolt, Telekes, Anás, Bar, Jair, Gottfried, Maya, Heching, Norman Isaac, Bettini, Anna Cecilia, Minelli, Mauro, Roila, Fausto, Verderame, Francesco, Atagi, Shinji, Goto, Hisatsugu, Goto, Koichi, Hara, Yu, Hida, Toyoaki, Hotta, Katsuyuki, Kuyama, Shoichi, Morise, Masahiro, Nakahara, Yasuharu, Okamoto, Isamu, Shinoda, Masahiro, Umemura, Shigeki, Heniks, Lizza, Ungureanu, Anei, Luft, Alexander, Sakaeva, Dina, Smolin, Alexey, Statsenko, Galina, Vasilyev, Alexander, Vladimirova, Lyubov, Chovanec, Jozef, Urda, Michal, Ji, Jun Ho, Lee, Kyung Hee, Isla Casado, Dolores, Ponce Aix, Santiago, Hsia, Te-Chun, Wu, Shang-Yin, Çiçin, Irfan, Göksel, Tuncay, Özgüroğlu, Mustafa, Adamchuk, Hryhoriy, Bondarenko, Igor, Kryzhanivska, Anna, Shevnia, Serhii, Trukhin, Dmytro, Ursol, Grygorii, Voitko, Oleksandr, Vynnychenko, Ihor, Chen, Yuanbin, Chua, Winston, Dakhil, Shaker, Goldman, Jonathan W, Lakhanpal, Shailena, Powell, Steven, Stilwill, Joseph

“…Most patients with small-cell lung cancer (SCLC) have extensive-stage disease at presentation, and prognosis remains poor. Recently, immunotherapy has…”
Get full text

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial by Chen, Yuanbin, Reinmuth, Niels, Hotta, Katsuyuki, Özgüroğlu, Mustafa, Ji, Jun Ho, Garassino, Marina Chiara, Poltoratskiy, Artem, Ponce, Santiago, Bondarenko, Igor, Conev, Nikolay V, Armstrong, Jon, Byrne, Natalie, Jiang, Haiyi, Paz-Ares, Luis, Voitko, Nataliia, Poltoratskiy, Artem, Bondarenko, Igor, Chen, Yuanbin, Özgüroglu, Mustafa, Conev, Nikolay, Burghuber, Otto, Moiseenko, Vladimir, Reinmuth, Niels, Ursol, Grygorii, Pajkos, Gábor, Verderame, Francesco, Smolin, Alexey, Göksel, Tuncay, Dakhil, Shaker, Lee, Jong-Seok, Garcia Campelo, Maria Rosario, Alacacioglu, Ahmet, Casarini, Ignacio, Ilieva, Rumyana, Somfay, Attila, Roila, Fausto, Urda, Michal, Majem Tarruella, Margarita, Bettini, Anna Cecilia, Okamoto, Isamu, Mandziuk, Slawomir, Domine Gomez, Manuel, Wu, Shang-Yin, Knoble, Jeanna, Venkova, Violetka, Laack, Eckart, Bischoff, Helge, Fülöp, Andrea, Telekes, András, Kanda, Shintaro, Nakahara, Yasuharu, Lin, Sheng-Hao, Schaefer, Eric, Nikolinakos, Petros, Schneider, Jeffrey, Kultan, Juraj, Kolek, Vitezslav, Lee, Kyung Hee, Goloborodko, Olexandr, Kolesnik, Oleksii, Ostapenko, Yuriy, Stilwill, Joseph, De Marchi, Pedro Rafael Martins, Krasteva, Rositsa, Koubkova, Leona, Grohe, Christian, Heching, Norman Isaac, Harada, Daijiro, Nogami, Naoyuki, Nokihara, Hiroshi, Goto, Hisatsugu, Staal van den Brekel, Agnes, Ganea, Doina, Popova, Ekaterina, Sakaeva, Dina, Stresko, Marian, Demo, Pavol, Hsia, Te-Chun, Lee, Kang-Yun, Zarba, Juan Jose, Pastor, Andrea Viviana, Zukin, Mauro, Calabrich, Aknar, Dudov, Asen, Lang, Susanne, Kanazawa, Kenya, Hiltermann, Jeroen, Shparyk, Yaroslav, Kryzhanivska, Anna, Jamil, Rodney, Williamson, Michael, Han, Zhigang, Wang, Mengzhao, Li, Wei, Feng, Jifeng, Zhou, Xiangdong, Hu, Yi, Nan, Kejun, Zhang, Wei, Lin, Zhong

“…First-line durvalumab plus etoposide with either cisplatin or carboplatin (platinum–etoposide) showed a significant improvement in overall survival versus…”
Get full text